Provided by Tiger Trade Technology Pte. Ltd.

Moleculin Biotech

4.81
+0.25005.48%
Pre-market: 4.830.0200+0.42%05:12 EST
Volume:514.70K
Turnover:2.57M
Market Cap:14.81M
PE:-0.06
High:5.30
Open:4.78
Low:4.65
Close:4.56
52wk High:55.50
52wk Low:3.13
Shares:3.08M
Float Shares:3.03M
Volume Ratio:11.39
T/O Rate:16.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-78.8608
EPS(LYR):-158.0236
ROE:-503.80%
ROA:-69.18%
PB:-0.55
PE(LYR):-0.03

Loading ...

Moleculin Biotech Issues New Investor Corporate Presentation

TIPRANKS
·
11 hours ago

Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Moleculin Biotech (MBRX)

TIPRANKS
·
17 hours ago

BRIEF-Moleculin Miracle Trial Delivers 40% Preliminary Blinded CRc Rate (N=30)

Reuters
·
Yesterday

Moleculin Biotech Inc - Reports 40% Preliminary Crc Rate in Miracle Trial

THOMSON REUTERS
·
Yesterday

Moleculin Biotech Inc - Expects Recruitment of First 45 Subjects by Q1 2026

THOMSON REUTERS
·
Yesterday

Moleculin MIRACLE trial reports 40% preliminary blinded CRc rate in relapsed or refractory AML

Reuters
·
Yesterday

Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin

THOMSON REUTERS
·
Feb 17

Moleculin Biotech Receives Notice of Allowance for Japanese Patent Covering Liposomal Annamycin

Reuters
·
Feb 17

Moleculin Biotech Inc. Launches CEO Corner to Enhance Stakeholder Communication and Outlines Plans to Advance Lead Clinical Programs and Pipeline Development

Reuters
·
Feb 13

Moleculin Biotech Inc. Held Special Stockholder Meeting

Reuters
·
Feb 06

Moleculin Biotech nimmt an virtueller Corporate-Connect-Konferenz von Webull Financial teil

Reuters
·
Feb 05

BUZZ-Moleculin Biotech rises as cancer drug shows no heart damage in trials

Reuters
·
Jan 13

Moleculin Biotech Reports Annamycin Shows No Cardiotoxicity in 90 Clinical Trial Subjects

Reuters
·
Jan 13

BRIEF-Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding On Track, Global Trial Expansion, And Multiple Externally/Iit Funded Clinical Programs

Reuters
·
Jan 12

Moleculin Biotech Inc - First Miracle Trial Unblinding Expected Q1 2026; Global Trial NOW Spans Nine Countries

THOMSON REUTERS
·
Jan 12

Moleculin Biotech Inc - Primary Efficacy Data for Miracle Expected in 2028

THOMSON REUTERS
·
Jan 12

BRIEF-Moleculin Biotech Regains Nasdaq Listing Compliance

Reuters
·
Jan 07

Moleculin Biotech Inc - Regains Nasdaq Listing Compliance - SEC Filing

THOMSON REUTERS
·
Jan 07

Moleculin Biotech Inc. Announces Date for Upcoming Special Stockholders Meeting

Reuters
·
Dec 20, 2025

Moleculin Reports Positive Phase 1 Results for WP1066 in Pediatric Brain Tumors

Reuters
·
Dec 17, 2025